Pivotal trial data suggesting a survival advantage with Bristol-Myers Squibb Co./Pfizer Inc.’s Eliquis (apixaban) over warfarin in the atrial fibrillation population was thought to set the Factor Xa inhibitor apart from the two other novel oral anticoagulants recently approved by FDA. In the end, however, the mortality data and its presentation were not all that different from Boehringer Ingelheim GMBH’s direct thrombin inhibitor Pradaxa (dabigatran).
While the apixaban mortality findings in ARISTOTLE were statistically significant, they just barely met this threshold. In review documents, agency staff used such words as “marginal” and “fragile” to describe the benefit
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?